December 2006 – A study conducted by the Rock Mountain Cancer Centers found that Taxotere caused 6% of women to suffer permanent alopecia. Reference: “Taxotere Lawsuit – Permanent Hair Loss and Illegal Marketing.” Drugwatch.com, 20 Apr. 2020, www.drugwatch.com/taxotere/lawsuits/
Continue ReadingOctober 2006 — Taxotere was approved for use in combination with cisplatin and fluorouracil for patients being treated for inoperable, locally advanced squamous cell carcinoma of the head and neck (SCCHN). Reference: “TAXOTERE® Receives U.S. FDA Approval for the Treatment of Patients with Head and Neck Cancer.” Sanofi, www.news.sanofi.us/press-releases?item=118381
Continue ReadingMay 2006 — Zostavax was approved by the FDA for patients 60 and older. Reference: Reference: Center for Biologics Evaluation and Research. “Zostavax.” U.S. Food and Drug Administration, FDA, www.fda.gov/vaccines-blood-biologics/vaccines/zostavax.
Continue ReadingMarch 2006 — Taxotere was approved for use in combination with cisplatin and fluorouracil for patients being treated for advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy. Reference: “Taxotere Wins FDA Approval for Advanced Gastric Cancer.” Cancer Network, www.cancernetwork.com/view/taxotere-wins-fda-approval-advanced-gastric-cancer
Continue ReadingAugust 2004 — Taxotere was approved for use in combination with doxorubicin and cyclophosphamide for the adjuvant treatment of women with operable node-positive breast cancer. Reference: Martins, Ines. “Docetaxel (Taxotere).” Breast Cancer News, 19 Apr. 2016, breastcancer-news.com/docetaxel-taxotere/
Continue ReadingMay 2004 – Taxotere was approved for use in combination with prednisone for the treatment of metastatic, androgen-independent prostate cancer. Reference: Martins, Ines. “Docetaxel.” Prostate Cancer News Today, 11 Mar. 2016, prostatecancernewstoday.com/docetaxel/
Continue ReadingDecember 1999 – Taxotere was approved as an injection to treat patients suffering from locally advanced or metastatic non-small cell lung cancer following failure of prior platinum-based chemotherapy. Reference: “FDA Approves New Taxotere® (Docetaxel) Injection Concentrate Formulation – Aug 5, 2010.” Sanofi, www.news.sanofi.us/press-releases?item=118530
Continue ReadingJune 1998 – Taxotere was approved for first-line treatment of metastatic breast cancer in subjects whose disease had recurred despite adjuvant therapy. Reference: “Taxotere (Docetaxel).” CenterWatch RSS, www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4266-taxotere-docetaxel
Continue ReadingMay 1996 – Taxotere was approved for use by the U.S. Food & Drug Administration. Reference: “Taxotere Gets FDA Approval for Treatment of Advanced Breast Cancer.” Cancer Network, www.cancernetwork.com/view/taxotere-gets-fda-approval-treatment-advanced-breast-cancer
Continue Reading